Vedolizumab - Pharmacy Freak

Mechanism of Action of Vedolizumab (Entyvio)

April 10, 2026July 11, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction Vedolizumab is a humanized IgG1 monoclonal antibody used for the treatment of moderate to severe ulcerative colitis and Crohn’s disease. It selectively targets the gastrointestinal immune system, offering gut-specific immunomodulation with minimal systemic immunosuppression. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion Bioavailability Not applicable (IV administration) Half-life ~25.5 days Volume … Read more

Mechanism of Action of Entyvio (Vedolizumab)

April 10, 2026July 4, 2025 Pharmacy Freak Editorial Team Harsh Singh Rajput

Introduction Entyvio (vedolizumab) is a recombinant humanized IgG1 monoclonal antibody that targets the α4β7 integrin on gut-homing T-lymphocytes. It is approved for moderate to severe ulcerative colitis and Crohn’s disease, particularly in patients who have not responded to or cannot tolerate TNF antagonists. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Intravenous infusion (300 mg) … Read more